Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. SPY
2. USO
3. IONQ
4. IONS
5. AZN
6. ROIV
7. AAPL
8. HOOD
9. QCOM
10. ACN

Go back to Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance

August 13, 2026 7:34 AM EDT

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($2.32), $1.01 worse than the analyst estimate of ($1.31). Revenue for the quarter came in at $33.4 million versus the consensus estimate of $33.12 million.

GUIDANCE:

Karyopharm Therapeutics sees FY2026 revenue of $130-150 million, versus the consensus of... More